Skip to main content
IMS Events Main banner

    Martine Elias, M.Sc. (she/her/hers)

    Chief Executive Officer
    Myeloma Canada
    Montreal, Quebec, Canada

    Martine Elias (M.Sc.) is the CEO at Myeloma Canada, the only patient-driven, grassroots organization bringing the Canadian myeloma community together and promoting a strong, unified national voice for people living with multiple myeloma. She has been with the organisation since 2016. In addition, Martine is the Co-Chair of the Access to Treatment and Innovation Oncology Network (ACTION), a Canadian based organisation. In 2019 Martine was one of three patient representatives on the PMPRB Guideline Development Steering committee. Martine believes intentional collaboration is key to evolving the knowledge of myeloma for the betterment of patients. In February 2020 she was invited to join the International Myeloma Foundation Board of Directors and more recently she was appointed Chair to their Governance and Nominating Committee. She also serves to represent Canada on the Myeloma Patient Europe Community Advisory Board since 2019 where patient advocates address key challenges patients face in accessing diagnosis, monitoring, treatment, care and clinical trial at an international level.

    Martine started her career in clinical research in the pharmaceutical industry and has since dedicated her professional life to patient advocacy, empowering the patient voice, and helping patients gain access to essential medical treatments. She is passionate about ensuring that the patient voice is included in all aspects of health policy decisions.

    Previously, Martine was Director Access, Advocacy and Community Relations at Myeloma Canada where she developed, led and executed all advocacy strategies and programs. Prior to that Martine held roles as National Director of Community Relations at Janssen Inc., and Market Access and Health Economics team leader at GSK.

    Disclosure information not submitted.

    Presentation(s):